Drugs / JNJ-61178104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02758392 | Apr 2016 → Jan 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-61178104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02758392 ↗ |
| Route | Intravenous | “JNJ-61178104 Intravenously on Day 1” NCT02758392 ↗ |